DVT Prophylaxis in ICU Patients

Standard Prophylactic Regimens

The American College of Critical Care Medicine recommends administering enoxaparin 40 mg subcutaneously once daily or unfractionated heparin (UFH) 5000 IU subcutaneously every 8 hours, with LMWH preferred over UFH to reduce healthcare worker exposure and missed doses 1, 2
Enoxaparin 40 mg subcutaneously once daily is the first-line option for most ICU patients, as it provides consistent anticoagulation with once-daily dosing that reduces healthcare worker exposure and minimizes missed doses 1, 2, 3
Dalteparin 5000 IU subcutaneously once daily is an equally effective alternative 1, 2
LMWH is specifically recommended over UFH in critically ill patients based on evidence showing reduced pulmonary embolism rates (hazard ratio 0.51, 95% CI 0.30-0.88) 1
UFH 5000 IU subcutaneously every 8 hours is more effective than twice-daily dosing and should be used when LMWH is contraindicated or in specific high-risk populations 1, 2, 4, 5
Three times daily UFH dosing was demonstrated to reduce DVT incidence from 29% to 13% in ICU patients compared to no prophylaxis 5

For patients with creatinine clearance <30 mL/min, the American College of Critical Care Medicine recommends using either UFH 5000 IU every 8 hours or reducing enoxaparin to 30 mg subcutaneously once daily 1, 2, 6
UFH is preferred in severe renal impairment as it is primarily metabolized by the liver rather than renally excreted 2, 5, 6
Dalteparin has low renal metabolism and can be used at standard doses (5000 IU daily) even with creatinine clearance <30 mL/min 1

For patients with BMI >30 kg/m², the American College of Critical Care Medicine recommends escalating to enoxaparin 40 mg subcutaneously every 12 hours or using weight-based dosing at 0.5 mg/kg subcutaneously every 12 hours 2, 3, 6
Some guidelines recommend a 50% dose increase for obese patients receiving LMWH prophylaxis 3

Standard prophylactic dosing (enoxaparin 40 mg daily or UFH 5000 IU every 8 hours) is strongly recommended for septic patients, as they have even higher VTE risk than general ICU populations 1, 5
UFH 5000 IU subcutaneously every 8 hours is specifically preferred over twice-daily dosing in cancer patients 2, 4
LMWH (enoxaparin 40 mg daily or dalteparin 5000 IU daily) is an acceptable alternative for cancer patients with normal renal function 2

When pharmacologic prophylaxis is contraindicated, the American College of Critical Care Medicine recommends using graduated compression stockings or intermittent pneumatic compression devices instead 1
Restart pharmacologic prophylaxis as soon as the bleeding risk decreases 1
Consider combining mechanical and pharmacologic prophylaxis in very high-risk patients when bleeding risk is acceptable 1

Routine anti-Xa monitoring is NOT required for standard prophylactic dosing in most ICU patients 2
Consider anti-Xa monitoring only in patients with extreme body weights or fluctuating renal function 2
Continue prophylaxis throughout the entire ICU stay and until the patient is fully ambulatory or discharged 2, 6
For post-surgical ICU patients, maintain prophylaxis for at least 7-10 days minimum 2, 6